KR20120101392A - 항미생물성 화합물 및 이의 제조 방법 및 사용 방법 - Google Patents

항미생물성 화합물 및 이의 제조 방법 및 사용 방법 Download PDF

Info

Publication number
KR20120101392A
KR20120101392A KR1020127012676A KR20127012676A KR20120101392A KR 20120101392 A KR20120101392 A KR 20120101392A KR 1020127012676 A KR1020127012676 A KR 1020127012676A KR 20127012676 A KR20127012676 A KR 20127012676A KR 20120101392 A KR20120101392 A KR 20120101392A
Authority
KR
South Korea
Prior art keywords
unsaturated
group
membered saturated
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127012676A
Other languages
English (en)
Korean (ko)
Inventor
에린 엠. 더피
아소케 바타카르지
하드윈 오다우드
마르코 데비보
졸탄 에프. 칸요
자켓 지. 마르니노우
익-현 백
매튜 에이치. 쉐이더만
산드라 신시타지
브라이언 티. 윔벌리
유셍 우
Original Assignee
립-엑스 파마슈티칼즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 립-엑스 파마슈티칼즈, 인크. filed Critical 립-엑스 파마슈티칼즈, 인크.
Publication of KR20120101392A publication Critical patent/KR20120101392A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/68Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6862Stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0046Ear
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • C07D239/36One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020127012676A 2009-10-16 2010-10-15 항미생물성 화합물 및 이의 제조 방법 및 사용 방법 Ceased KR20120101392A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25247809P 2009-10-16 2009-10-16
US61/252,478 2009-10-16
US31428710P 2010-03-16 2010-03-16
US61/314,287 2010-03-16
US35820110P 2010-06-24 2010-06-24
US61/358,201 2010-06-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177033784A Division KR101972992B1 (ko) 2009-10-16 2010-10-15 항미생물성 화합물 및 이의 제조 방법 및 사용 방법

Publications (1)

Publication Number Publication Date
KR20120101392A true KR20120101392A (ko) 2012-09-13

Family

ID=43876906

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127012676A Ceased KR20120101392A (ko) 2009-10-16 2010-10-15 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
KR1020127012700A Ceased KR20120099435A (ko) 2009-10-16 2010-10-15 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
KR1020127012702A Expired - Fee Related KR101857694B1 (ko) 2009-10-16 2010-10-15 항미생물성 화합물 및 이의 제조 방법 및 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020127012700A Ceased KR20120099435A (ko) 2009-10-16 2010-10-15 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
KR1020127012702A Expired - Fee Related KR101857694B1 (ko) 2009-10-16 2010-10-15 항미생물성 화합물 및 이의 제조 방법 및 사용 방법

Country Status (10)

Country Link
JP (6) JP2016121171A (enrdf_load_stackoverflow)
KR (3) KR20120101392A (enrdf_load_stackoverflow)
CN (5) CN105646370A (enrdf_load_stackoverflow)
AR (3) AR080558A1 (enrdf_load_stackoverflow)
EA (1) EA201500913A1 (enrdf_load_stackoverflow)
MY (2) MY161870A (enrdf_load_stackoverflow)
NZ (2) NZ713357A (enrdf_load_stackoverflow)
PH (1) PH12012500732A1 (enrdf_load_stackoverflow)
SG (3) SG10201406634VA (enrdf_load_stackoverflow)
TW (8) TW201125566A (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358697B (es) 2009-10-16 2018-08-31 Melinta Therapeutics Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
JP6274723B2 (ja) 2009-10-16 2018-02-07 メリンタ セラピューティクス,インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
KR20120101392A (ko) * 2009-10-16 2012-09-13 립-엑스 파마슈티칼즈, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
CN109053695A (zh) * 2011-04-15 2018-12-21 梅琳塔治疗公司 抗微生物化合物及制备和使用所述化合物的方法
WO2015035426A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compunds and methods of making and using the same
CA2923179A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
AU2016228584A1 (en) 2015-03-11 2017-10-05 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3452479A1 (en) 2016-05-06 2019-03-13 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
US3673184A (en) * 1970-09-02 1972-06-27 Dainippon Pharmaceutical Co Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives
EP0067610A1 (en) * 1981-06-16 1982-12-22 Beecham Group Plc Penicillins, a process for their preparation and compositions containing them
ZA835684B (en) * 1982-08-27 1985-03-27 Roussel Uclaf Imidazo(1,2-a)pyrimidines
IT1197876B (it) * 1986-10-15 1988-12-21 Pharmachim Engineering Srl Procedimento per la preparazione dell'acido 5,8-diidro-8-etil-5-osso-2-(1-piperazinil)pirido(2,3-d)pirimidin-6-carbossilico
JP2549931B2 (ja) * 1990-01-12 1996-10-30 株式会社大塚製薬工場 ピリミドベンズイミダゾール誘導体
JP2991382B2 (ja) * 1990-07-18 1999-12-20 大日本製薬株式会社 縮合三環式化合物およびその塩
JP2811230B2 (ja) * 1990-10-17 1998-10-15 コニカ株式会社 新規な写真用カプラー
US5208141A (en) * 1990-10-09 1993-05-04 Konica Corporation Silver halide color photographic light-sensitive material
US6451968B1 (en) * 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
IT1263804B (it) * 1993-01-22 1996-09-03 Luso Farmaco Inst Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
CA2162846A1 (en) * 1993-05-12 1994-11-24 James Francis Bereznak Fungicidal fused bicyclic pyrimidinones
US5502177A (en) * 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5668127A (en) * 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
WO1999024452A2 (en) * 1997-11-07 1999-05-20 Isis Pharmaceuticals, Inc. Pyrimidine derivatives for labeled binding partners
DE19838998A1 (de) * 1998-08-27 2000-03-09 Bayer Ag Neue Naturstoffderivate
SE9903894D0 (sv) * 1999-10-28 1999-10-28 New Pharma Research Ab Novel compounds
EP1411954B1 (en) * 2000-10-18 2010-12-15 Pharmasset, Inc. Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
DE10061542A1 (de) * 2000-12-11 2002-06-13 Bayer Ag Alkanoylamino-pyrimidine
DE10061538A1 (de) * 2000-12-11 2002-06-20 Bayer Ag Ureido-Dihydropyrimidinone
DE60113450T2 (de) * 2000-12-14 2006-07-13 The Procter & Gamble Company, Cincinnati Antimikrobielle chinolone
EP1363640B1 (en) * 2001-01-29 2010-04-28 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
TWI248936B (en) * 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
WO2002097134A2 (en) * 2001-05-25 2002-12-05 Isis Pharmaceuticals, Inc. Modified peptide nucleic acid
JP2005504020A (ja) * 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
JP4306206B2 (ja) * 2001-09-04 2009-07-29 住友化学株式会社 イミダゾ[1,2−a]ピリミジン、その用途およびその製造中間体
GB0205165D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
WO2004080466A1 (en) * 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
US20050075363A1 (en) * 2003-08-12 2005-04-07 Bradbury Barton James Isothiazoloquinolones and related compounds as anti-infective agents
EP1913004B1 (en) * 2005-07-27 2010-09-22 Achillion Pharmaceuticals, Inc. 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-infective agents
WO2007101871A1 (de) * 2006-03-08 2007-09-13 Basf Se Substituierte imidazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
WO2008082440A2 (en) * 2006-08-25 2008-07-10 Emory University Fluorescent nucleoside analogues
EP1964841A1 (en) * 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
KR20090098710A (ko) * 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
KR20120101392A (ko) * 2009-10-16 2012-09-13 립-엑스 파마슈티칼즈, 인크. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법

Also Published As

Publication number Publication date
KR20120099436A (ko) 2012-09-10
TWI612048B (zh) 2018-01-21
NZ713357A (en) 2017-05-26
TW201622725A (zh) 2016-07-01
CN107266470A (zh) 2017-10-20
TW201630914A (zh) 2016-09-01
TW201726630A (zh) 2017-08-01
CN104628729A (zh) 2015-05-20
CN104628729B (zh) 2018-11-06
JP2019038808A (ja) 2019-03-14
TW201731849A (zh) 2017-09-16
SG10201406634VA (en) 2014-11-27
JP2018024653A (ja) 2018-02-15
TWI618707B (zh) 2018-03-21
CN108456211A (zh) 2018-08-28
JP2018039784A (ja) 2018-03-15
TWI621439B (zh) 2018-04-21
SG10201406635QA (en) 2014-11-27
TW201125566A (en) 2011-08-01
TWI629277B (zh) 2018-07-11
EA201500913A1 (ru) 2015-12-30
JP2016153405A (ja) 2016-08-25
CN105646370A (zh) 2016-06-08
CN107445976A (zh) 2017-12-08
TW201825495A (zh) 2018-07-16
PH12012500732A1 (en) 2020-10-19
TW201125564A (en) 2011-08-01
KR20120099435A (ko) 2012-09-10
SG10201406631TA (en) 2014-11-27
KR101857694B1 (ko) 2018-06-19
MY161870A (en) 2017-05-15
MY165011A (en) 2018-02-28
JP2016121171A (ja) 2016-07-07
AR080617A1 (es) 2012-04-25
AR080558A1 (es) 2012-04-18
AR080559A1 (es) 2012-04-18
NZ623384A (en) 2016-06-24
JP2016172733A (ja) 2016-09-29
TWI589294B (zh) 2017-07-01
TW201124417A (en) 2011-07-16

Similar Documents

Publication Publication Date Title
KR101972992B1 (ko) 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
KR20180069098A (ko) 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
US10259825B2 (en) Antimicrobial compounds and methods of making and using the same
KR20120101392A (ko) 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
HK40001086A (en) Antimicrobial compounds and methods of making and using the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120516

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151013

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161121

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170628

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161121

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170628

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170221

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20151013

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120703

Comment text: Amendment to Specification, etc.

E601 Decision to refuse application
E801 Decision on dismissal of amendment
PE0601 Decision on rejection of patent

Patent event date: 20171021

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20161121

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PE0801 Dismissal of amendment

Patent event code: PE08012E01D

Comment text: Decision on Dismissal of Amendment

Patent event date: 20171021

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170927

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20170221

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20151013

Patent event code: PE08011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20120703

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171122